Meeting
2011 Breast Cancer Symposium
Correlation of efficacy between rash and lapatinib/capecitabine therapy in Japanese HER2-positive metastatic breast cancer patients.
Authors
S. E. Nagai
Saitama Cancer Center, Saitama, Japan
S. E. Nagai , K. Inoue , S. Kaneko , S. Uchida , T. Higuchi , Y. Hayashi , T. Yoshida , H. Takei , M. Kurosumi , T. Tabei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A
Track
Detection, Screening, and Imaging
Sub Track
Predictive and Prognostic Factors
Citation
J Clin Oncol 29, 2011 (suppl 27; abstr 62)
Abstract #
62
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
First Author: Min Yan
Poster
2016 ASCO Annual Meeting
Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.
First Author: Bora Lim
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop
Poster
2020 ASCO Virtual Scientific Program
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).
First Author: Santiago Escrivá